文献速递白血病造血干细胞移植与细胞治疗

维奈克拉联合FLAG-IDA诱导和巩固治疗新诊断急性髓系白血病

Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia.
PubMed 文献 · Am J Hematol · 2022-05-30

一项前瞻性单中心Ib/II期研究评估氟达拉滨、阿糖胞苷、G-CSF和伊达比星联合维奈克拉(FLAG-IDA + VEN)方案。45例新诊断或复发/难治性急性髓系白血病患者入组,新诊断扩展队列结果显示总缓解率98%(44/45,95%可信区间89.9%-99.7%),89%(40/45)达到复合完全缓解,其中93%(37/40)为可测量残留病阴性,60%(27/45)桥接至异基因造血干细胞移植。中位随访20个月,中位无事件生存期和总生存期均未达到,估计24个月无事件生存率和总生存率分别为64%和76%。

要点

  • FLAG-IDA + VEN在新诊断急性髓系白血病中总缓解率达98%(44/45)。
  • 89%(40/45)达复合完全缓解,其中93%(37/40)可测量残留病阴性。
  • 60%(27/45)患者桥接至异基因造血干细胞移植,毒性可管理。

核心结论

  • FLAG-IDA + VEN是新诊断急性髓系白血病的有效方案,能产生高可测量残留病阴性缓解率,并在多数合适患者中实现向异基因造血干细胞移植的过渡。
  • 毒性符合诱导化疗预期且可管理,估计24个月生存率与历史诱导化疗基准相比似乎有利。

研究设计与样本

  • 前瞻性单中心Ib/II期研究,评估FLAG-IDA + VEN用于新诊断或复发/难治性急性髓系白血病患者。
  • 主要疗效终点为总体活动性(总缓解率:完全缓解+部分血液学恢复的完全缓解+血液学恢复不完全的完全缓解+形态学无白血病状态+部分缓解)。
  • 次要目标包括额外疗效评估、总生存期和无事件生存期,本报告为扩展新诊断队列的额外随访结果。
  • 共45例患者入组,中位年龄44岁(范围20-65岁)。

主要发现

  • 总缓解率为98%(N=44/45;95%可信区间89.9%-99.7%)。
  • 89%(N=40/45)患者达到复合完全缓解(完全缓解+部分血液学恢复的完全缓解+血液学恢复不完全的完全缓解),其中93%(N=37/40)为可测量残留病阴性。
  • 27例(60%)患者过渡至异基因造血干细胞移植。
  • 常见非血液学不良事件包括发热性中性粒细胞减少(44%;N=20)、肺炎(22%;N=10)、菌血症(18%;N=8)和皮肤/软组织感染(44%;N=20)。
  • 中位随访20个月后,中位无事件生存期和总生存期均未达到;估计24个月无事件生存率和总生存率分别为64%和76%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Multi-agent induction chemotherapy (IC) improves response rates in younger patients with acute myeloid leukemia (AML); however, relapse remains the principal cause of treatment failure. Improved induction regimens are needed. A prospective single-center phase Ib/II study evaluating fludarabine, cytarabine, G-CSF, and idarubicin combined with venetoclax (FLAG-IDA + VEN) in patients with newly diagnosed (ND) or relapsed/refractory AML. The primary efficacy endpoint was assessment of overall activity (overall response rate [ORR]: complete remission [CR] + CR with partial hematologic recovery [CRh] + CR with incomplete hematologic recovery [CRi] + morphologic leukemia free state + partial response). Secondary objectives included additional assessments of efficacy, overall survival (OS), and event-free survival (EFS). Results of the expanded ND cohort with additional follow-up are reported. Forty-five patients (median age: 44 years [range 20-65]) enrolled. ORR was 98% (N = 44/45; 95% credible interval 89.9%-99.7%). Eighty-nine percent (N = 40/45) of patients attained a composite CR (CRc + CRh + CRi) including 93% (N = 37/40) who were measurable residual disease (MRD) negative. Twenty-seven (60%) patients transitioned to allogeneic stem cell transplant (alloHSCT). Common non-hematologic adverse events included febrile neutropenia (44%; N = 20), pneumonia (22%, N = 10), bacteremia (18%, N = 8), and skin/soft tissue infections (44%, N = 20). After a median follow-up of 20 months, median EFS and OS were not reached. Estimated 24-month EFS and OS were 64% and 76%, respectively. FLAG-IDA + VEN is an active regimen in ND-AML capable of producing high MRD-negative remission rates and enabling transition to alloHSCT when appropriate in most patients. Toxicities were as expected with IC and were manageable. Estimated 24-month survival appears favorable compared to historical IC benchmarks.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. DiNardo CD, Lachowiez CA, Takahashi K, et al. Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia. Am J Hematol. 2022. PMID: 35583199. doi:10.1002/ajh.26601

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。